![How To Align the SEO Process With AI Discovery [Infographic]](https://imgproxy.divecdn.com/9P2R5ZZoepHyBzf0CW-n2EgWRhr-_OdwsznROe_GvnM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9haV9zZWFyY2hfaW5mbzIucG5n.webp)
Why BioHaven Stock Is Soaring Today
Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.Biohaven revealed it has secured up to $600 million from the investment firm Oberland Capital Management. The deal includes an immediate $250 million with the remainder tied to regulatory milestones and strategic acquisitions. Critically, the deal is non-dilutive, meaning that Oberland doesn't get new shares -- a move that would reduce the value of existing shareholders' portfolios. Announced via press release, the deal provides "significant financial resources" to advance clinical trials and prepare for a potential FDA approval of troriluzole for spinocerebellar ataxia (SCA).Continue reading
Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.
Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.
Biohaven revealed it has secured up to $600 million from the investment firm Oberland Capital Management. The deal includes an immediate $250 million with the remainder tied to regulatory milestones and strategic acquisitions. Critically, the deal is non-dilutive, meaning that Oberland doesn't get new shares -- a move that would reduce the value of existing shareholders' portfolios. Announced via press release, the deal provides "significant financial resources" to advance clinical trials and prepare for a potential FDA approval of troriluzole for spinocerebellar ataxia (SCA).
